Tarsus Patent-Cliff Exposure & CMS Drug Spending Portfolio
Tarsus (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $123.4M 2024 CMS Part D & Medicaid spend, and $1,850 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2038-01-01 |
| 2024 CMS Total Public Spend | $123.4M |
| 2024 Medicare Part D Spend | $114.3M |
| 2024 Medicaid Spend | $9.2M |
| California HCAI SB 17 Filings | Specialty launch notice ($1,850 intro WAC) |